“Afrigen Biologics has earned GMP certification from the South African Health Products Regulatory Authority (SAHPRA), validating Africa’s first fully integrated mRNA manufacturing facility in Cape Town. This achievement enhances Africa’s pandemic preparedness, enabling local production of investigational biological products for clinical trials and reducing reliance on imported vaccines.”
South Africa has taken a decisive leap forward in biotechnology with Afrigen Biologics securing Good Manufacturing Practice (GMP) certification for its Cape Town-based mRNA manufacturing facility. This milestone is not only a national triumph but also a continental breakthrough, symbolizing Africa’s growing capacity to produce advanced vaccines and biologics. GMP certification validates compliance with global safety and quality standards, enabling Afrigen to manufacture investigational biological products for Phase I and II clinical trials.
Why GMP Certification Matters
- Global Standards Compliance: GMP certification ensures adherence to internationally recognized safety and quality benchmarks.
- Clinical Trial Readiness: Afrigen can now manufacture investigational biological products for clinical trials, a critical step toward vaccine innovation.
- Health Sovereignty: By reducing reliance on imports, South Africa strengthens its ability to respond to pandemics and supply vaccines locally.
Lessons from COVID-19
The COVID-19 pandemic exposed Africa’s vulnerability in vaccine access. Wealthy nations secured doses early, while African countries faced delays and shortages. Afrigen’s facility directly addresses this inequity, ensuring that future pandemics do not leave Africa dependent on external suppliers.
Afrigen’s Journey
- 2022–2023: Conceptualization of the mRNA Technology Transfer Programme, co-led by the World Health Organization (WHO) and the Medicines Patent Pool (MPP).
- 2024–2025: Infrastructure development, recruitment of scientists, and establishment of pilot production lines.
- 2026: GMP certification achieved, marking readiness for clinical trial material production.
Strategic Importance
Afrigen’s facility is more than a national achievement—it is a continental asset.
- Pandemic Preparedness: Rapid response capability for emerging infectious diseases.
- Regional Manufacturing Hub: A platform for vaccine production across Africa.
- Innovation Ecosystem: Collaboration between academia, government, and industry to advance biotechnology.
Voices of Leadership
Prof. Petro Terblanche, CEO of Afrigen, emphasized: “This certification is a tribute to the extraordinary commitment of our team. We are ready to support clinical trial production and contribute meaningfully to vaccine development.”
Economic and Social Impact
- Job Creation: Hundreds of skilled positions in biotechnology, engineering, and regulatory compliance.
- Local Innovation: Stimulating South Africa’s biotech ecosystem, encouraging investment in biologics and diagnostics.
- Continental Reach: Serving not only South Africa but also broader African and global markets.
Integration with Global Health Initiatives
Afrigen’s achievement aligns with WHO’s global push for equitable vaccine access. By establishing Africa’s first end-to-end mRNA facility, South Africa positions itself as a critical partner in global health security.
Challenges Ahead
Despite the milestone, Afrigen faces challenges:
- Scaling Production: Moving from pilot-scale to mass production requires significant investment.
- Regulatory Hurdles: Maintaining compliance with evolving international standards.
- Global Competition: Competing with established pharmaceutical giants in Europe, Asia, and North America.
Conclusion
Afrigen’s GMP certification represents a turning point in Africa’s biotechnology journey. It is a bold statement of intent: Africa will no longer remain a passive consumer of imported vaccines but will emerge as a producer, innovator, and global partner in health security.
